Please login to the form below
mylife YpsoPump
This page shows the latest mylife YpsoPump news and features for those working in and with pharma, biotech and healthcare.
Ypsomed’s touch screen insulin pump for Novo Nordisk approved by EMA
The European Medicines Agency has approved YpsoPump's touch screen insulin pump, mylife YpsoPump. ... The mylife YpsoPump is fitted with a touch screen, reducing the need for training, and is fully compatible with Novo Nordisk's prefilled pump cartridge,
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Publications director
-
Competitive salary and bonus scheme
-
Account Director
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
-
Account director
-
Competitive salary and bonus scheme
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Senior External Communications Lead
-
£Competitive Salary
- Client Services Director - Digital MedComms
-
£60000 - £80000 per annum, Benefits: Pension, healthcare, dedicated training budget, regul
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Director, Medical Education
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
Subscribe to our email news alerts
- Novartis faces criticism over Zolgensma ‘health lottery’
- Genital herpes vaccine candidate heads for human studies
- Botox strength bolsters Allergan ahead of AbbVie takeover
- AZ revenues rise, but it says coronavirus could hit 2020
- A market-adapted agile approach to launch excellence
- Novartis pulls ahead of Merck in MET-positive lung cancer race
- SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease
- US states reject drug distributors’ opioid settlement
- BMS unveils long-term results for Opdivo in kidney cancer
- Enabling market access through outcomes-based pricing
- Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
- After FDA refusal, Takeda builds case for subcutaneous Entyvio
No results were found
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Enabling market access through outcomes-based pricing
- Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
- 20 for 2020 – Five pharma companies to watch
- As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
- The growing clinical importance of patient-reported outcomes (PROs)
- Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Quick links
Infographics
